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ABSTRACT
Objective To investigate whether dietary
supplementation with B vitamins or omega 3 fatty acids,
or both, could prevent major cardiovascular events in
patients with a history of ischaemic heart disease or
stroke.
Design Double blind, randomised, placebo controlled
trial; factorial design.
Setting Recruitment throughout France via a network of
417 cardiologists, neurologists, and other physicians.
Participants 2501 patients with a history of myocardial
infarction, unstable angina, or ischaemic stroke.
Intervention Daily dietary supplement containing
5-methyltetrahydrofolate (560 μg), vitamin B-6 (3 mg),
and vitamin B-12 (20 μg) or placebo; and containing
omega 3 fatty acids (600 mg of eicosapentanoic acid and
docosahexaenoic acid at a ratio of 2:1) or placebo.
Median duration of supplementation was 4.7 years.
Main outcome measures Major cardiovascular events,
definedasacompositeofnon-fatalmyocardialinfarction,
stroke, or death from cardiovascular disease.
Results Allocation to B vitamins lowered plasma
homocysteine concentrations by 19% compared with
placebo, but had no significant effects on major vascular
events (75 v 82 patients, hazard ratio, 0.90 (95%
confidence interval 0.66 to 1.23, P=0.50)). Allocation to
omega 3 fatty acids increased plasma concentrations of
omega 3 fatty acids by 37% compared with placebo, but
alsohadnosignificanteffectonmajorvascularevents(81
v 76 patients, hazard ratio 1.08 (0.79 to 1.47, P=0.64)).
ConclusionThisstudydoesnotsupporttheroutineuseof
dietary supplements containing B vitamins or omega 3
fatty acids for prevention of cardiovascular disease in
people with a history of ischaemic heart disease or
ischaemic stroke, at least when supplementation is
introduced after the acute phase of the initial event.
Trial registration Current Controlled Trials
ISRCTN41926726.
INTRODUCTION
Observational studies have reported inverse associa-
tions of cardiovascular disease with dietary intake or
plasma concentrations of B vitamins (folate and vita-
min B-6) and omega 3 polyunsaturated fatty acids.
1-6
Moderately elevated concentrations of plasma total
homocysteine have been associated with higher risks
of coronary heart disease and stroke,
7-12 and dietary
supplementationwithfolicacidandvitaminB-12typi-
cally lowers plasma total homocysteine concentration
by about 25–30%,
13 raising the prospect that dietary
supplementation with these B vitamins might reduce
the risk of coronary heart disease and stroke.
14
Severallargescaletrialshaveexaminedtheeffectsof
supplementation with B vitamins on cardiovascular
disease, but none has reported any significant effects
on risk of cardiovascular disease.
15-23 Possible reasons
for the failure of these trials to show any significant
effects on vascular disease include lack of statistical
power to detect treatment effects (owing to an insuffi-
cient number of participants or duration of treatment),
attenuation of the effects of B vitamins by mandatory
folic acid fortification or by widespread use of supple-
mentscontainingfolicacidamongtrialparticipants,or
that homocysteine is not causally related to vascular
disease.
Observational studies have also reported inverse
associations of cardiovascular disease with dietary
intake or plasma concentrations of omega 3 fatty
acids (mainly eicosapentanoic acid and docosahexae-
noic acid), suggesting that supplementation with
omega 3 fatty acids might exert protective effects on
cardiovascular disease.
24-28 These fatty acids have
been shown to have beneficial effects on several
cardiovascular risk factors—including blood pressure,
plasma triglyceride concentration, and markers of
thrombosis and inflammation—and may also have
antiarrhythmic effects.
24-29 Although some trials invol-
ving patients with a history of cardiovascular diseases
or with high levels of cardiovascular risk factors have
reported positive effects of omega 3 fatty acids on
cardiovascular events,
3031 other trials have reported
no effects on arrhythmia or mortality.
2932-34
The aims of the Supplémentation en Folates et
Omega-3 (SU.FOL.OM3) trial were to investigate
1UMR U557 Inserm; U1125 Inra;
Cnam; Université Paris 13, CR
NH IdF, F-93017 Bobigny, France
2Département de Santé publique,
Hôpital Avicenne, 93017, F-
Bobigny, France
3EA 4003, Ecole de Santé
publique, Epidémiologie clinique,
Faculté de Médecine, CHU Nancy,
France
4Université Paris-Descartes,
Faculté de Médecine; AP-HP;
Hôt e l - D i e u ,C e n t r ed eD i a g n o s t i c
et Thérapeutique, Paris, France
Correspondence to: P Galan, U557
INSERM/INRA/CNAM/UP13,SMBH,
74, rue Marcel Cachin, 93017
Bobigny, France
p.galan@uren.smbh.univ-paris13.
fr
Cite this as: BMJ 2010;341:c6273
doi:10.1136/bmj.c6273
BMJ | ONLINE FIRST | bmj.com page 1 of 9whether dietary supplementation with homocysteine
lowering B vitamins or omega 3 fatty acids, or both,
could prevent major cardiovascular events in patients
with a history of ischaemic heart disease or stroke.
METHODS
Study design
The SU.FOL.OM3 trial was a multicentre, double
blind, randomised trial with a placebo controlled fac-
torialdesignthatevaluatedtheseparateandcombined
effects of daily dietary supplementation with B vita-
mins and omega 3 fatty acids for the prevention of
cardiovascular disease. Using a 2×2 factorial design,
we examined the effects of a daily dietary supplement
containing 5-methyltetrahydrofolate (560 μg), vitamin
B-6 (3 mg) and B-12 (20 μg) versus placebo, and a sup-
plement containing omega 3 polyunsaturated fatty
acids (600 mg of eicosapentanoic acid and docosahex-
aenoic acid at a ratio of 2:1) versus placebo. The
supplements were provided without charge by Merck
Eprova AG (5-methyltetrahydrofolate), Roche
Laboratory (vitamins B-6 and B-12), and Pierre Fabre
(omega3 fatty acids). Thegelatincapsules were manu-
factured by Catalent Pharma Solutions (Beinheim,
France).ThestudyprotocolwasapprovedbytheCon-
sultation Committee for the Protection of Participants
in Biomedical Research of the Paris-Cochin Hospital
and by the French National Information and Citizen
Freedom Committee. All participants provided writ-
ten informed consent.
Study population and design
Participants with a history of cardiovascular disease
were recruited via a network of 417 cardiologists, neu-
rologists, and other physicians in 257 centres through-
out France. Men and women aged 45–80 years who
had had an acute coronary or cerebral ischaemic
event within the 12 months before randomisation
were eligible to participate.
A coronary event was defined as either myocardial
infarction or acute coronary syndrome. Myocardial
infarction (ICD-10 (international classification of dis-
eases, 10th revision) codes I21.0–I21.9) was defined
on the basis of two or more of the criteria—typical
chest pain, electrocardiographic changes consistent
with myocardial infarction, and cardiac enzyme
increase. Acute coronary syndrome without myo-
cardialinfarction(ICD-10codesI20.0–I20.1)wasiniti-
ally defined by the presence of three criteria—typical
chest pain, electrocardiographic changes consistent
with coronary artery disease without myocardial
infarction, and evidence of coronary artery disease
(myocardial infarction, angina with angiographic evi-
dence of stenosis >50% in one or more coronary
arteries, or angina pectoris corroborated by coronary
angiography or exercise testing, or coronary angio-
plasty or coronary artery bypass graft procedure). In
2003 the inclusion criteria were amended to include
suspected acute coronary syndrome without
characteristic electrocardiographic evidence of myo-
cardialinfarctionprovidedtherewasangiographicevi-
dence of coronary artery disease.
An acute cerebralischaemiceventwasdefinedasan
ischaemic cerebrovascular accident based on clinical
criteria confirmed by computed tomography or mag-
netic resonance imaging and a Rankin score ≤3a t
inclusion (ICD-10 codes I63.0–I63.9). Individuals
with transient ischaemic attacks were not eligible for
inclusion.
Exclusion criteria
Exclusioncriteriaincludedage(<45yearsor>80years),
illdefineddiagnosisofcardiovasculardisease,inability
or unwillingness to comply with study treatment, and
disease or treatment that might interfere with meta-
bolism of homocysteine or omega 3 fatty acids, in par-
ticular methotrexate fortreating cancer or rheumatoid
arthritis and chronic renal failure (plasma creatinine
concentration >200 μmol/l or creatinine clearance
<40 ml/min).
Randomisation and blinding
Included participants were randomly assigned to
receive B vitamins alone, omega 3 fatty acids alone,
bothactivetreatments,or placeboforbothtreatments.
Study treatment was given as two capsules to be taken
oncedaily.Randomisationwasperformedbymeansof
a computerised block sequence stratified by three age
groups (44–54, 55–64, and 65–80 years), sex, prior dis-
ease at enrolment (myocardial infarction, acute coron-
ary syndrome, or ischaemic stroke) and recruitment
centre. Permuted block randomisation (with block
size randomly selected as 8) was used. Patients, clini-
cians, trial coordinators, and outcome investigators
were blinded to treatment allocation. The allocation
ofparticipantswasprogrammedbythestatisticalcoor-
dinating centre. Once participants were randomised,
the coordinating centre sent them sufficient treatment
capsules for one year (and repeated yearly) in an
appropriately labelled package.
Assessment
Everysixmonthsafterenrolment,wemailedquestion-
naires to all the participants, asking about any serious
disease outcomes, treatment compliance, presence of
cardiovascular risk factors, and adverse effects. A non-
mandatory visit was scheduled annually in one of the
257 centres, and participants who were unable or
unwilling to attend and who did not return the ques-
tionnairewereinterviewedbytelephonebystudyphy-
sicians. The general practitioners, cardiolologists, or
neurologists treating the participants were asked to
report any relevant information on health events that
might have occurred every six months. Once a possi-
bleeventwassuspected,wesoughtallrelevantmedical
records,includingresultsofdiagnostictestsandproce-
dures, from the treating physician or general practi-
tioner or directly from the participant.
Compliance with treatment was self reported in the
biannual questionnaires (or by telephone interview).
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allocated treatment. Blood samples were obtained
from all participants at baseline, and from a sample of
participants attending their health centre visit at
12 months (n=2147) and at the end of the trial
(n=1160) for assessment of plasma concentrations of
total homocysteine and pyridoxal phosphate and
serum concentrations of folate and vitamin B-12.
Fatty acid composition of plasma lipids was also deter-
mined by gas chromatography in a random sample
(n=682) at baseline and at 12 months. In addition, all
participants had plasma concentrations of cholesterol
(total, low density lipoprotein, and high density lipo-
protein) and triglycerides and fasting blood glucose
concentrations measured at enrolment. Participants
were censored on the date of their first major event,
death, or, for those without an event, at the end of fol-
low-up on 1 July 2009.
End points
The primary end point was the first major cardio-
vascular event—non-fatal myocardial infarction,
ischaemicstroke,ordeathfromcardiovasculardisease
(including fatal myocardial infarction, stroke, sudden
death (within one hour of onset of acute symptoms in
the absence of violence or accident), aortic dissection,
cardiacfailure,orotherfataleventdefinedbythemed-
ical committee as having a cardiovascular cause). Sec-
ondary end points included acute coronary syndrome
without myocardial infarction, resuscitation from sud-
den death, coronary artery bypass surgery, coronary
angioplasty, cardiac failure, ventricular arrhythmia,
supraventricular arrhythmia, cardiac surgery of any
kind,transientischaemicattack,deepveinthrombosis,
pulmonaryembolism,carotidsurgeryorcarotidartery
angioplasty,peripheralarterialsurgeryorangioplasty,
any vascular procedure, and death from all causes. All
events were adjudicated by two independent commit-
tees of cardiologists or neurologists who were blinded
to treatment allocation. In addition, incident cases of
cancer were also recorded, and all cases were con-
firmed by pathology reports.
Statistical analysis
The sample size was calculated for the estimated event
rate of 0.087 in the placebo group, based on the event
rates observed in previous trials in similar populations
and in epidemiological studies.
35-37 No interaction
between B vitamins and omega 3 fatty acids was anti-
cipated. The planned enrolment of 2500 participants
with an average follow-up of five years was expected
to have more than 90% power to detect a 10% reduc-
tion in the relative risk of major vascular events asso-
ciatedwithBvitaminsoromega3fattyacidsanda19%
reduction for the combination of omega 3 fatty acids
and B vitamins, given a two sided α value of 0.05.
35
For analysis of the primary outcome, participants
contributed to person time up to the date of diagnosis,
dateoflastcompletedquestionnaire,dateofdeath,or1
July2009, whicheveroccurred first.For analysisofthe
secondary outcomes, participants who experienced
events other than those included in the primary end
point were censored at the date of diagnosis. For ana-
lyses of revascularisation and other cardiovascular
events, participants were counted only if they had not
already experienced a primary outcome.
Allanalyseswereconductedaccordingtotheprinci-
ple of intention to treat. The main comparisons were
the effects of B vitamins versus placebo and omega 3
fatty acids versus placebo, but the 2×2 factorial design
also allowed comparison between the combined sup-
plementation group with the placebo group. We esti-
mated the hazard ratios and 95% confidence intervals
using Cox proportional hazards models after adjust-
ment for age and sex. We used Kaplan-Meier survival
analysis to compare the cumulative incidence of the
primary end point by treatment allocation. Assump-
tions of proportionality were verified graphically.
All the analyses were performed with SAS software
(version 8.2). This study is registered with Current
Controlled Trials (No ISRCTN41926726).
Patients assessed for eligibility (n=3374)
Patients randomised (n=2501)
Allocated placebo (n=626) Allocated B vitamins (n=622)
Complete follow-up (n=547)
Allocated omega 3
fatty acids (n=633)
Allocated B vitamins +
omega 3 fatty acids (n=620)
Excluded (n=873):
  Did not meet inclusion criteria (n=337)
  Refused to participate (n=536)
Not followed (n=73):
  Withdrew consent (n=31)
  Lost to follow-up (n=5)
  Died (n=37)
Complete follow-up (n=572)
Not followed (n=61):
  Withdrew consent (n=30)
  Lost to follow-up (n=2)
  Died (n=29)
Complete follow-up (n=542)
Not followed (n=80):
  Withdrew consent (n=33)
  Lost to follow-up (n=3)
  Died (n=44)
Complete follow-up (n=561)
Not followed (n=65):
  Withdrew consent (n=33)
  Lost to follow-up (n=8)
  Died (n=24)
Fig 1 | Flow chart of study participants.
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Characteristics of the participants
Between1February2003and1June2007,2501parti-
cipants (1987 men and 514 women) were recruited.
Overall, the mean (SD) age of participants was 60.9
(8.8) years for men and 63.2 (9.7) years for women.
Of the 2501 participants, 1150 (46%) had had a prior
myocardial infarction, 713 (28%) an acute coronary
syndrome without myocardial infarction, and 638
(26%) an ischaemic stroke. The median time between
the acute event and randomisation in the trial was
101 days. Participants were randomly assigned to one
of four treatments: B vitamins (n=622), omega 3 fatty
acids (n=633), B vitamins and omega 3 fatty acids (n=
620), or double placebo (n=626) (fig 1). The four
groups were well balanced with respect to the baseline
characteristics, risk factors, and medication use
(table 1). The median follow-up time was 4.7 years
(mean 4.2 (SD 1.0) years) with a total of 10656 person
years.Allparticipantscompletedtheirscheduledtreat-
ment by 1 July 2009.
Compliance and side effects
Theoverallresponserateforreturnofcompletedques-
tionnaires was 99%, 96%, 94%, and 95% at 6, 12, and
24 months and at the end of the trial, respectively.
About 86% of those who returned a questionnaire
reportedthattheywerecompliantwiththestudytreat-
ment (defined as taking at least 80% of the allocated
treatment), and compliance was similar in all four
Table 1 |Baseline characteristics of 2501 trial participants by allocation to dietary supplementation with B vitamins, omega
3 fatty acids, or both. Values are median (interquartile range) except when specified otherwise
B vitamins + omega 3
fatty acids (n=620)
Omega 3 fatty acids
(n=633)
B vitamins
(n=622)
Placebo
(n=626)
Age (years) 60.5 (53.9-68.9) 60.41 (5.7-68.7) 60.7 (54.7-68.3) 60.9 (54.5-68.1)
No (%) of men 493 (79.5) 501 (79.2) 497 (79.9) 496 (79.2)
No (%) with inclusion criteria:
Myocardial infarction 280 (45.2) 300 (47.4) 288 (46.3) 282 (45.0)
Unstable angina 176 (28.4) 185 (29.2) 168 (27.0) 184 (29.4)
Stroke 164 (26.4) 148 (23.4) 166 (26.7) 160 (25.6)
No (%) reaching elementary school level
of education*
375 (62.1) 364 (59.0) 370 (60.8) 376 (61.1)
No (%) smoking:
Current smokers 69 (11.4) 70 (11.3) 67 (10.9) 63 (10.1)
Former smokers 374 (61.5) 368 (59.2) 378 (61.4) 397 (63.9)
Non-smokers 165 (27.1) 183 (29.5) 171 (27.7) 161 (26.0)
Blood pressure (mm Hg):
Systolic 130.0 (118.0-147.0) 130.5 (118.5-149.0) 131.0 (117.5-146.5) 132.0 (118.5-144.0)
Diastolic 82.0 (75.0-91.0) 83.0 (75.0-91.5) 82.5 (74.0-91.5) 81.5 (74.5-89.0)
Body mass index (kg/m
2) 27.1 (24.7-29.8) 27.1 (25.1-29.7) 27.3 (25.0-29.75) 27.2 (24.0-29.7)
Waist:hip ratio 0.95 (0.91-0.99) 0.96 (0.91-1.00) 0.96 (0.91-0.99) 0.96 (0.91-1.00)
No (%) using medication:
β blockers 409 (66.0) 431 (68,1) 422 (67.9) 428 (68.4)
Calcium and channel blockers 86 (13.9) 103 (16.3) 79 (12.7) 86 (13.7)
Lipid lowering agents 531 (85.7) 544 (85.9) 518 (83.3) 544 (86.9)
Aspirin or antiplatelet agents 569 (91.8) 595 (94.0) 584 (93.9) 588 (93.9)
ACE inhibitors 340 (54.8) 331 (52.3) 328 (52.7) 342 (54.6)
Angiotensin II receptor blockers 61 (9.8) 44 (7.0) 64 (10.3) 70 (11.2)
Plasma concentrations (mmol/l):
Total cholesterol 4.5 (3.9-5.3) 4.5 (3.9-5.4) 4.6 (3.9-5.3) 4.5 (3.9-5.1)
HDL cholesterol 1.2 (1.0-1.4) 1.2 (1.0-1.3) 1.2 (1.0-1.4) 1.1 (1.0-1.3)
LDL cholesterol 2.7 (2.2-3.3) 2.7 (2.2-3.3) 2.7 (2.2-3.3) 2.6 (2.2-3.2)
Fasting glucose 5.4 (5.1-6.1) 5.4 (5.0-5.9) 5.4 (5.1-5.9) 5.4 (5.0-5.9)
Triglycerides 1.2 (0.9-1.6) 1.2 (0.9-1.6)) 1.3 (0.9-1.7)) 1.1 (0.9-1.7))
Biochemical characteristics† † (n= =611) (n= =622) (n= =612) (n= =616)
Serum folate (ng/ml) 6.7 (5.2-8.7) 6.6 (5.1-8.6) 6.7 (5.2-8.5) 7.0 (5.3-9.0)
Plasma vitamin B-6 (nmol/l) 37.2 (28.0-50.6) 38.7 (27.8-53.8) 38.0 (29.1-52.7) 37.7 (28.5-53.5)
Serum vitamin B-12 (pg/ml) 361 (291-455) 365 (290-468) 359 (298-455) 376 (306-474)
Plasma total homocysteine (µmol/l) 12.9 (10.7-16.0) 12.9 (10.9-15.8) 13.0 (11.2-16.0) 12.6 (10.4-15.5)
Creatinine (µmol/l) 78.0 (70.0-87.0) 77.0 (68.0-88.0) 78.0 (70.0-88.0) 78.0 (69.0-88.0)
ACE=angiotensin converting enzyme. HDL=high density lipoprotein. LDL=low density lipoprotein.
*Equivalent to primary education.
†Some missing data owing to insufficient blood collection or laboratory technical problems.
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gastrointestinal disturbances, nausea, and cutaneous
reactions) accounted for 2.1% of participants stopping
treatment(2.6%inthegrouptakingomega3fattyacids
group, 2.0% in the B vitamins group, and 1.6% in the
placebo group).
Effect of intervention on B vitamin status and fatty acid
profiles
The median (interquartile range) baseline concentra-
tions of serum folate were 6.7 (5.2–8.7) ng/ml, vitamin
B-12was365(296–463)pg/ml,andplasmatotalhomo-
cysteine was 12.8 (10.8–15.8) μmol/l. Allocation to B
vitamins was associated with a 20% lower (2.5 μmol/l)
median plasma total homocysteine concentration at
1 year compared with those allocated placebo, and
this difference was 19% (2.7 μmol/l) at the end of the
trial (table 2). Allocation to B vitamins was associated
with 146% increase in serum folate, 35% increase in
serum vitamin B-12, and 116% increase in plasma
vitamin B-6. Allocation to omega 3 fatty acids was
associated with a 37% increase in median plasma
concentrations of these fatty acids at one year com-
pared with those allocated to placebo.
Effects of B vitamins on primary and secondary end points
Primary end point
During a median of 4.7 years of follow-up, 157 partici-
pants (6.3%) experienced a major confirmed cardio-
vascular event, with 20 individuals experiencing
more than one cardiovascular event. Allocation to B
vitamins was not associated with any significant effect
on major vascular events (75 v 82 individuals, hazard
ratio 0.90 (95% confidence interval 0.66 to 1.23),
P=0.50; fig 2). B vitamins had no significant effect on
the cumulative incidence of the primary end points
throughout the scheduled treatment period (fig 3).
Secondary end points
Amongthesecondaryoutcomes,therewere60casesof
non-fatalmyocardialinfarction,57casesofstroke,117
deaths(40duetocardiovascularcauses),and436addi-
tional cardiovascular events, including coronary
angioplasty (n=174), coronary artery bypass surgery
(n=38), acute coronary syndrome without myocardial
infarction (n=37), supraventricular arrhythmia (n=33),
and acute cardiac failure (n=31).
Allocation to B vitamins had no significant effect on
non-fatal myocardial infarction (28 v 32 patients,
hazard ratio 0.88 (0.53 to 1.46), P=0.61; fig 2), but it
was associated with fewer stroke events (21 v 36
patients, hazard ratio 0.57 (0.33 to 0.97), P=0.04).
There were no significant differences in the rates of
all other cardiovascular events, analysed individually
or combined. However, supplementation with B vita-
mins was associated with a non-significantly higher
mortality from cardiovascular causes (26 v 14 patients,
hazard ratio 1.81 (0.95 to 3.47), P=0.07) and a signifi-
cantly higher risk of death from any cause (72 v 45
patients, hazard ratio 1.55 (1.07 to 2.25), P=0.02).
Furthermore, allocation to B vitamins did not have
any significant effects on cancer morbidity (92 v
77patients, hazard ratio 1.19 (0.88 to 1.60), P=0.27).
Effect of omega 3 fatty acids on primary and secondary
end points
Allocation to omega 3 fatty acids was not associated
with any significant effect on major vascular events
(81 v 76 patients, hazard ratio 1.08 (0.79 to 1.47),
P=0.64; fig 4). Moreover, there were no significant dif-
ferences in the cumulative incidence of the primary
end point between the active and placebo groups at
any time during follow-up (fig 3).
In addition, allocation to omega 3 fatty acids had no
significant effect on any secondary end points, includ-
ing other cardiovascular events and mortality from all
causes(fig4),noroncancermorbidity(88v81patients,
hazard ratio 1.10 (0.81 to 1.48), P=0.55).
DISCUSSION
Inthistrialwefoundnosignificant effectsofdailydiet-
ary supplementation with B vitamins or with omega 3
fatty acids on risk of major cardiovascular events in
Table 2 |Participants’ concentrations of biochemical markers at baseline, at one year, and at
the end of treatment by allocation to dietary supplementation with B vitamins, omega 3 fatty
acids, or both. Values are medians (interquartile ranges)
B vitamins
+ omega 3
fatty acids
Omega 3
fatty acids B vitamins Placebo
Plasma total homocysteine
(μmol/l):
Baseline* 12.9 (10.7-16.0) 12.9 (10.9-15.8) 13.0 (11.2-16.0) 12.6 (10.4-15.5)
1 year† 9.8 (8.2-11.5) 12.3 (10.3-15.1) 9.7 (8.1-11.8) 12.1 (9.7-14.8)
End of supplementation‡ 11.9 (10.3-14.0) 14.2 (12.0-17.6) 11.4 (9.9-14.4) 14.5 (12.4-18.3)
Serum folate (ng/ml):
Baseline* 6.7 (5.2-8.7) 6.6 (5.1-8.6) 6.7 (5.2-8.5) 7.0 (5.3-9.0)
1 year† 16.9 (12.2-21.9) 6.8 (5.3-8.7) 16.5 (12.0-21.9) 6.7 (5.2-8.4)
End of supplementation‡ 16.1 (12.3-1.5) 6.4 (4.9-8.4) 15.4 (11.4-19.4) 6.5 (5.2-8.1)
Plasma vitamin B-6 (nmol/l):
Baseline* 37.2 (28.0-50.6) 38.7 (27.8-53.8) 38.0 (29.1-52.7) 37.7 (28.5-53.5)
1 year† 81.1 (57.4-106.2) 39.4 (28.9-53.8) 69.4 (50.5-92.1) 37.3 (28.2-53.2)
End of supplementation‡ 87.3 (58.0-121.3) 38.2 (28.2-52.5) 76.3(49.7-102.4) 36.9 (27.6-50.9)
Serum vitamin B-12 (pg/ml):
Baseline* 361 (291-455) 365 (290-468) 359 (298-455) 376 (306-474)
1 year† 506 (405-646) 381 (296-488) 491 (390-639) 378 (303-481)
End of supplementation‡ 504 (397-620) 367 (286-468) 497 (390-615) 370 (312-469)
Fatty acid composition of plasma lipids (% of total)§ §
Eicosapentanoic acid:
Baseline 1.15 (0.80-1.69) 1.14 (0.83-1.71) 1.12 (0.75-1.68) 1.26 (0.84-1.81)
1 year 2.08 (1.65-2.76) 2.15 (1.77-2.75) 1.16 (0.78-1.68) 1.20 (0.88-1.66)
Docosahexaenoic acid:
Baseline 2.53 (2.05-3.28) 2.55 (2.04-3.23) 2.53 (2.00-3.23) 2.70 (2.15-3.36)
1 year 3.07 (2.70-3.74) 3.12 (2.70-3.76) 2.55 (1.96-3.23) 2.77 (2.06-3.29)
Eicosapentanoic +
docosahexaenoic acids:
Baseline 3.68 (2.93-4.97) 3.73 (2.92-4.91) 3.64 (2.86-4.78) 4.04 (2.99-5.08)
1 year 5.13 (4.42-6.38) 5.34 (4.53-6.52) 3.66 (2.85-4.99) 3.92 (2.99-4.81)
*n=2461 (respectively 611, 622, 612, and 616 for the four groups).
†n=2147 (respectively 531, 544, 534, and 538 for the four groups).
‡n=1160 (respectively 282, 292, 294, and 292 for the four groups).
§n=682 (respectively 163, 173, 177, and 169 for the four groups).
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disease during a median 4.7 years of follow-up.
Uniquely, the trial tested the separate and combined
effects of both B vitamins and omega 3 fatty acids for
preventionofstrokeandmyocardialinfarction.Incon-
trastwithprevioustrialsofBvitamins, thepresenttrial
used a lower dose and a more naturally occurring
formulation of folic acid. Previous trials used higher
doses of B vitamins
15-23 and omega 3 polyunsaturated
acids.
31 A meta-analysis of trials that assessed the
effects of folic acid on blood homocysteine concentra-
tionsshowedthatdailysupplementationwith0.5–5mg
of folic acid reduced homocysteine concentrations by
aboutaquarter,andtheadditionofvitaminB-12(20μg
to 1 mg daily) to folic acid reduced blood homocys-
teine concentration by a further 7%.
38
Instead of folic acid, we used 5-methyltetrahydrofo-
late, which is the predominant form present in circula-
tionandthemostabundantnaturalfolateformandisas
effective as folic acid in decreasing blood homocys-
teine concentration and is unlikely to mask vitamin
B-12 deficiency.
39 The dose of omega 3 fatty acids we
used correspondedto a diet containing a large amount
of fatty fish, which has been associated with a reduced
risk of cardiovascular diseases in observational
studies.
3242627
Strengths and limitations of the trial
Ourtrialhadseveralimportantstrengths.First,thetrial
wascarriedoutinFrance,acountrywithnomandatory
fortification of foods with folic acid or widespread use
of folic acid supplements, both of which may have
complicatedmanyothertrialsofBvitaminsupplemen-
tation for prevention of vascular disease.
15-23 Second,
none of the previous trials assessed the effects of 5-
methyltetrafolate, which has a closer resemblance to
the naturally occurring 5-methyltetrahydrofolic acid
and has been shown to be as effective as folic acid but
without the potential disadvantage of masking anae-
mia from vitamin B-12 deficiency.
39 Other strengths
of the study include the high self reported compliance
with treatment (corroborated by increased blood con-
centrations of B vitamins or omega 3 polyunsaturated
fattyacids,andlowerplasmahomocysteineconcentra-
tions in the B vitamin supplementation groups after
treatment),the smallnumberofparticipantslosttofol-
low-up,theavailabilityofcompleteendpointdata;and
theadjudicationofendpointsbyprofessionalsblinded
to treatment allocation.
However,thetrialincludedarelativelymodestnum-
ber of participants and was continued for relatively
short duration to provide appropriate statistical
power to detect effects on major vascular events. In
particular, the observed number of major vascular
events was 15% lower than expected, which adversely
affectedthe statisticalpowertodetecta 10% difference
in major vascular events. Consequently, we cannot
excludethepossibilitythatthedurationofsupplemen-
tation and follow-up and the doses used for B vitamins
and omega 3 polyunsaturated fatty acids were insuffi-
cient. While the biochemical analysis was carried out
inasubsampleofthetrialpopulation,itispossiblethat
thissubsetwithbiochemical measureshadbettercom-
pliance than the rest of the participants, which may
haveled tooverestimation ofthedifferencesin plasma
homocysteine concentrations achieved in the overall
trial population.
Primary end point
  Major cardiovascular events*
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  All coronary events†
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  All cerebrovascular events‡
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48 (3.8)
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45 (3.6)
Placebo
(n=1259)
No of events (%)
*Composite of non-fatal myocardial infarction, stroke, or death from cardiovascular disease
†All myocardial infarctions or acute coronary syndrome without myocardial infarction
‡Fatal and non-fatal stroke events (ischaemic or haemorrhagic), transient ischaemic attacks
§Coronary and peripheral arteries revascularisation, angioplasties
¶Acute coronary syndrome without myocardial infarction, resuscitated from sudden death, coronary bypass surgery,
   percutaneous transluminal angioplasty, acute cardiac failure, ventricular or supraventricular arrhythmia, cardiac  
   surgery of any kind, transient ischaemic attack, deep vein thrombosis, pulmonary embolism, carotid surgery or
   angioplasty, peripheral arterial surgery or angioplasty, any vascular procedure
Fig 2 | Effect of dietary supplementation with B vitamins on cardiovascular events and mortality
(adjusted for age and sex)
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Fig 3 | Kaplan-Meier curves for cumulative incidence of first
major cardiovascular event (non-fatal myocardial infarction,
ischaemic stroke, or death from cardiovascular disease)
associated with dietary supplementation with B vitamins (top)
or omega 3 fatty acids (bottom)
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The absence of any significant effects of B vitamins on
major vascular events that we observed is consistent
with the results of previous large scale trials of B vita-
mins in patients with pre-existing vascular
disease,
15-182223 in those at high risk of cardiovascular
disease,
19 in patients with end stage renal disease,
20 or
after coronary angiography.
21 Only the NORVIT trial
reported a trend towards an increased rate of primary
outcomes among patients receiving B vitamins.
17 In
addition, two small trials of folic acid and vitamin B-6
reported a reduction in the rate of restenosis after cor-
onary artery angioplasty but an increase in this rate
after coronary stenting.
4041
In our trial, allocation to B vitamins was associated
with a 46% reduction in the risk of ischaemic stroke
among patients assigned to B vitamins and a trend
towards increased cardiovascular mortality, with an
unexpected, significant increase in the number of
deathsfromanycauseamongpatientsreceivingBvita-
mins (not specifically linked to cancer). The latter two
resultsmustbeinterpretedwithcaution,sincethenum-
ber of statistical tests performed on secondary end
points was large and the number of events was small,
and the confidence intervals around the relative risk
estimates are wide.
However, the HOPE-2 trial, of 5522 patients with
prior vascular disease treated with B vitamins for five
years, had reported a 24% reduction in the risk of
stroke.
18 Nevertheless, a reduction in stroke risk was
not observed in the Vitamin Intervention for Stroke
Prevention (VISP) trial, in which stroke was the pri-
mary end point.
16
In the VISP trial, 3680 patients with non-disabling
stroke were randomised to receive high dose vitamins
(2.5 mg folic acid, 0.4 mg vitamin B-12, and 25 mg
vitamin B-6 daily) or low dose vitamins (20 μg folic
acid, 6 μg vitamin B-12, and 200 μg vitamin B-6
daily), without a placebo group. The trial ended
early, and there was no significant effect on the risk of
recurrent stroke during the two years of follow-up. It
has been suggested that the lack of effect observed in
the VISP trial could be explained by the relatively
small observed difference in plasma total homocys-
teine concentrations associated with higher dose vita-
mins (only 15%, 13.1 v 11.0 μmol/l), which was lower
than expected, possibly owing to fortification of foods
with folic acid.
16 Furthermore, the study did not
include a placebo group, and correction of low levels
ofserumvitaminB-12inthelowdosegroupmayhave
attenuated the vitamin effect.
A meta-analysis of eight trials, published in 2007,
involving 778 first strokes, showed that folic acid sup-
plementation was associated with an 18% reduced risk
of stroke.
42
In the stratified analyses, greater beneficial effects
were observed in trials with a duration of treatment
greater than three years, a decrease in the concentra-
tion of plasma total homocysteine of more than 20%,
absence of folic acid fortification, and in participants
without history of stroke. However, a meta-analysis
of eight large homocysteine lowering trials completed
before 2009 and involving 37485 participants and
1528 first stroke events reported that lowering homo-
cysteine concentrations had no beneficial effects on
first stroke.
43 The VITATOPS trial, published in
2010, involving 8164 patients with recent stroke or
transient ischaemic attack (within the past seven
months) treated with B vitamins (2 mg folic acid,
25 mg vitamin B-6, and 0.5 mg vitamin B-12) for a
median duration of 3.4 years, found no significant
reduction in the risk for non-fatal or fatal stroke.
23
The present trial also showed that omega 3 fatty
acids had no significant effects on any of the primary
or secondary end points. The results of previous trials
ofomega3fattyacidshavebeenconflicting.In2004,a
meta-analysis involving 36913 participants receiving
omega 3 fatty acids in the form of supplement or
enriched food for at least six months reported no
reduction in total mortality or cardiovascular
events.
29 Subsequently, the effects of omega 3 fatty
acids for prevention of cardiovascular disease have
been examined in several additional large scale trials.
In the GISSI trial, which included 11324 patients
who had had a myocardial infarction within the pre-
vious three months, treatment with 1 g daily of
omega 3 fatty acids reduced the risk of death, non-
fatal myocardial infarction, and non-fatal stroke by
10%, and the cumulative rate of cardiovascular death,
non-fatal myocardial infarction, and non-fatal stroke
by 15%.
31 Although the trial did not include a placebo
group, results provided strong support for an anti-
arrhythmic effect of the fatty acids.
The JELIS trial of 18645 Japanese participants with
elevated serum cholesterol concentrations and receiv-
ingstatinsbutwithoutevidenceofcoronaryarterydis-
ease reported that supplementation with 1.8 g daily of
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  Major cardiovascular events*
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*Composite of non-fatal myocardial infarction, stroke, or death from cardiovascular disease
†All myocardial infarctions or acute coronary syndrome without myocardial infarction
‡Fatal and non-fatal stroke events (ischaemic or haemorrhagic), transient ischaemic attacks
§Coronary and peripheral arteries revascularisation, angioplasties
¶Acute coronary syndrome without myocardial infarction, resuscitated from sudden death, coronary bypass surgery,
   percutaneous transluminal angioplasty, acute cardiac failure, ventricular or supraventricular arrhythmia, cardiac  
   surgery of any kind, transient ischaemic attack, deep vein thrombosis, pulmonary embolism, carotid surgery or
   angioplasty, peripheral arterial surgery or angioplasty, any vascular procedure
Fig 4 | Effect of dietary supplementation with omega 3 fatty acids on cardiovascular events and
mortality (adjusted for age and sex)
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dence of major cardiovascular events by 19% com-
pared with the group receiving statin alone.
44
In addition, the GISSI-HF study reported that long
term administration of 1 g a day of omega 3 fatty acids
in patients with chronic heart failure reduced all cause
mortality by 9% and hospitalisation for cardiovascular
reasons by 8%.
45 However, the type of patients
included in this trial differed from those included in
our trial.
Recently, the Alpha-Omega trial reported that daily
supplementationwith0.4gdailyofomega3fattyacids
in 4837 patients with a previous myocardial infarction
had no significant effect on major cardiovascular
events.
46
The discordant findings observed between the dif-
ferent trials may be partly explained by differences in
the doses of fatty acids tested or the interval between
theinitialeventandthestartofthesupplementation.In
theGISSItrial,themediantimefromtheonsetofmyo-
cardial infarction to randomisation was 16 days,
whereas in our trial it was more than six times longer
(101 days). In the GISSI trial, the beneficial effect on
mortality (including sudden death) appeared early on
after the start of supplementation; moreover, survival
curves for the omega 3 fatty acid treatment diverged
soon after randomisation.
47 This difference in the
time lapse could be important in light of physio-
pathological and clinical data suggesting a possible
protective effect of omega 3 fatty acids on cardiac
arrhythmias.
48
Conclusions and policy implications
The results of the present trial do not support the rou-
tine use of dietary supplements containing B vitamins
or omega 3 fatty acids for the prevention of cardio-
vascular disease in people with a history of ischaemic
heartdiseaseorischaemicstroke,especiallywhensup-
plementation starts after the acute phase of the initial
event.
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